New Delhi

President Trump’s move to impose 100% import tariffs on pharmaceutical drugs from October 1 is unlikely to have an immediate impact on Indian exports, as it will affect only patented and branded products, not generic medicines, pharma industry players said on Friday.

Indian Pharmaceutical Alliance (IPA), which represents 23 leading Indian pharmaceutical firms, including Dr Reddy’s Laboratories, Sun Pharma, Lupin and Zydus Lifesciences, noted that Trump’s latest tariff will not have implications for the generic drugmakers.

Reacting to the development, IPA Secretary General Sudarshan Jain said in a statement, “It is not applicable to generic medicines.” Trump’s statement refers to patented and branded products supplied to the US, he added. Indian pharma companies largely export

See Full Page